Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Crizotinib,CRZ2020-US,2020,USA,MDV,350,62,52,48,27.5,60,85,5,15,35,30,20,40,30,20,10,20,35,45,12,5,3,7,4,10,45,55,Cisplatin + Pemetrexed,Carboplatin + Paclitaxel,Cisplatin + Vinorelbine,Carboplatin + Pemetrexed,0,0,0,30,65,50,15,40,45,60,2
Crizotinib,CRZ2021-EU,2021,Germany,Claim Database,420,65,48,52,28.1,55,80,7,12,38,32,18,35,32,23,10,18,37,45,15,6,4,8,5,12,48,52,Cisplatin + Gemcitabine,Carboplatin + Docetaxel,Cisplatin + Etoposide,Carboplatin + Vinorelbine,0,0,0,35,70,55,10,35,55,70,1.5
Crizotinib,CRZ2022-JP,2022,Japan,MDV,280,68,55,45,26.8,45,75,3,18,32,35,15,45,28,17,10,22,33,45,10,4,2,6,3,8,42,60,Carboplatin + Pemetrexed,Cisplatin + Docetaxel,Carboplatin + Paclitaxel,Cisplatin + Vinorelbine,0,0,0,40,60,45,20,45,35,55,2.5
Crizotinib,CRZ2023-CA,2023,Canada,Claim Database,480,63,50,50,29.0,58,82,6,14,36,31,19,38,31,22,9,19,36,45,13,5,3,7,4,11,46,54,Cisplatin + Pemetrexed,Carboplatin + Docetaxel,Cisplatin + Vinorelbine,Carboplatin + Pemetrexed,0,0,0,32,68,52,12,38,50,65,1.8
